{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125526","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.418420+00:00","generated_at":"2026-05-30T02:04:04.350130+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"IN8bio Q3 net loss $7.1M; cash $4.0M; closes $11.6M placement; INB-100/200 updates","bullets":["Net loss of $7.1M ($0.15 per share) vs $7.2M loss ($0.23) in Q3 2023.","Cash $4.0M at Sept 30; closed Oct private placement for $11.6M net proceeds, extending runway into Q1 2026.","R&D $3.3M (-13% YoY), G&A $2.7M (-21% YoY); severance charges $1.1M from workforce reduction.","All AML patients in INB-100 remain in CR; FDA provided registrational path; expansion to ~25 patients planned.","Suspended INB-400 Phase 2 enrollment for newly diagnosed GBM; monitoring continues at SNO and ASH meetings."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125526","json":"https://secwatch.observer/filing/0000950170-24-125526.json","markdown":"https://secwatch.observer/filing/0000950170-24-125526.md","text":"https://secwatch.observer/filing/0000950170-24-125526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000095017024125526/0000950170-24-125526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000095017024125526/inab-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:04:04.350130+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}